Acquisition by Tyson Timothy of 8000 shares of Syros Pharmaceuticals subject to Rule 16b-3
| SYRS Stock | USD 0.27 0.02 8.00% |
Slightly above 56% of all Syros Pharmaceuticals' private investors are looking to take a long position. The analysis of the overall investor sentiment regarding Syros Pharmaceuticals suggests that some traders are interested. Syros Pharmaceuticals' investing sentiment can be driven by a variety of factors including economic data, Syros Pharmaceuticals' earnings reports, geopolitical events, and overall market trends.
Syros |
Filed transaction by Syros Pharmaceuticals Inc director. Grant, award or other acquisition pursuant to Rule 16b-3(d)
Read at macroaxis.com
Syros Pharmaceuticals Fundamental Analysis
We analyze Syros Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Syros Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Syros Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Return On Asset
Return On Asset Comparative Analysis
Syros Pharmaceuticals is currently under evaluation in return on asset category among its peers. Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
Syros Pharmaceuticals Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Syros Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of Syros Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Syros Pharmaceuticals by comparing valuation metrics with similar companies.
Peers
Syros Pharmaceuticals Related Equities
| PASG | Passage Bio | 20.97 | ||||
| KRON | Kronos Bio | 10.34 | ||||
| SRZN | Surrozen | 8.96 | ||||
| LRMR | Larimar Therapeutics | 7.44 | ||||
| BOLT | Bolt Biotherapeutics | 5.00 | ||||
| RGNX | Regenxbio | 4.82 | ||||
| BDTX | Black Diamond | 4.05 | ||||
| KROS | Keros Therapeutics | 2.02 | ||||
| QNRX | Quoin Pharmaceuticals | 1.69 | ||||
| CRNX | Crinetics Pharmaceuticals | 1.59 | ||||
| XNCR | Xencor | 1.26 | ||||
| STOK | Stoke Therapeutics | 1.19 | ||||
| IDYA | Ideaya Biosciences | 0.78 | ||||
| SNDX | Syndax Pharmaceuticals | 0.06 | ||||
| KZR | Kezar Life | 0.40 | ||||
| CHRS | Coherus BioSciences | 1.56 | ||||
| SPRO | Spero Therapeutics | 1.74 | ||||
| KTTA | Pasithea Therapeutics | 3.65 | ||||
| RNXT | RenovoRx | 7.35 |
Additional Tools for Syros Stock Analysis
When running Syros Pharmaceuticals' price analysis, check to measure Syros Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Syros Pharmaceuticals is operating at the current time. Most of Syros Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Syros Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Syros Pharmaceuticals' price. Additionally, you may evaluate how the addition of Syros Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.